Vascepa, (miracle drug) continues to demonstrate therapeutic value: Association Between Oxidative Stress and Fatty Acid Metabolism in The Synovial Fluid in Knee Osteoarthritis https://t.co/fWNeVFtcsi $AMRN

@skathire @hmkyale @matthewherper Reduce It was designed to confirm a hypothesis. Hundreds of Studies worldwide continue to elucidate MOA of EPA - here's a recent one from Japan https://t.co/I0eJYI8CHT

When Reduce-It read-out shows sig reduction of Stroke: Boom! $AMRN https://t.co/svLjFRbeqD

Low EPA associated with venous thromboembolism (3rd leading cause of stroke) $AMRN https://t.co/IVXdrQvA6j https://t.co/xwY5WJxxZr

Study finds dog CVD health correlated to EPA:AA ratio (surprised?) $AMRN https://t.co/vVoxVj8YSq

Conclusions; inflammatory property of circulating monocytes associated with carotid plaques https://t.co/JX8QjbYXI1 $AMRN

EPA suppress de novo lipogenesis to ameliorate hepatic steatosis $AMRN https://t.co/pajpHIXzMa

Immunomodulatory Effectiveness of Fish Oil and omega-3 Fatty Acids in Human Non-melanoma Skin Carcinoma Cells $AMRN https://t.co/SuDs7hWA9u

EPA added to strong statin therapy https://t.co/JzuvMVZ7AI $AMRN

Effects of adding EPA to Strong Statin Therapy on Inflammatory Cytokines and Coronary Plaque Components $AMRN https://t.co/6AedLZTuPg

EPA Reduces epicardial adipose tissue a pathogenic fat depot associated with atherosclerosis and CVD events. http://t.co/0IWzLHsPad $AMRN

Eicosapentaenoic Acid Prevents Saturated Fatty Acid-Induced Vascular Endothelial Dysfunction (A+ for R-I ) $AMRN http://t.co/OwG8eVpl5c

WARNING! contains "EPA PORN" : full color images of fibrous caps made thicker by EPA -yikes! http://t.co/J1mAUgflso $AMRN

New article: EPA increased the fibrous cap thickness in patients with coronary atherosclerotic plaque. http://t.co/AJmYiGNn6P $AMRN

@DrSethdb CAD study show EPA with anti atherosclerotic properties https://t.co/1nySMh9LFn FYI http://t.co/Szn3eEsaT3

RT @EPADrug: CAD study shows EPA anti atherosclerotic properties, less EAT, AVAT & SAT volumes, improved insulin sensitivity #FDA https://t…

@ajbrzski Why would FDA ever approve a drug proven to reduce CVD risk and safe as placebo? get real... #FDA $AMRN https://t.co/PoBWQcM1SL

FYI just got confirmation from FDA, my submission to ADCOM was accepted $AMRN http://t.co/ze6NoJo2hH

@DLBHATTMD FYI interesting new review on EPA and CV events https://t.co/LAfr8w6fE4

The nail in coffin for DHA - I can't see any docs writing Rx for ANY drug w/ DHA after seeing this http://t.co/rXpiwPTxLp $AMRN

Who thinks its a good idea to email this study to FDA ADCOM panel particpants? You did already ? Damn... $AMRN http://t.co/ke4PR0Q79M

"@CaptBeer: $AMRN @drdavidsamadi EPA not DHA key to CVD reductions. http://t.co/rVd1EkDXyq. Vascepa 96% EPA"

If I was asked to be on ADCOM panel & then read this review , I'd demand to know why FDA was wasting my time $AMRN http://t.co/QnX1ycQjT9

@SheffStation @BioStocks @_whiteMlKE agree, but if delayed more time for Docs to save face & read this in advance https://t.co/LAfr8w6fE4

Any Doc on $AMRN ADCOM panel that hasnt read study this, prepare to be thoroughly embarassed & labeled incompetent http://t.co/Vqc79FeIfN

Long or Short $AMRN? Either way, read a new (remarkable) scientific paper; details how EPA not DHA reduces CV events http://t.co/3cPEo9TzmM

Study: why EPA (not DHA) reduces CV events; it's metabolism of EPA to bioactive PGI3. Must read short or long $AMRN http://t.co/AiZ9Xatsod

"@Ski: $AMRN "with the (PGI2+PGI3)/TXA2 ratio." http://t.co/nhSYpp9LhN" a good read

CAD study shows EPA anti atherosclerotic properties, less EAT, AVAT & SAT volumes, improved insulin sensitivity #FDA https://t.co/MVL0s0QAoF